TCIM
ACAD icon

TIAA CREF Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

TIAA CREF Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$20.5M Buy
763,896
+332,582
+77% +$7.77M 0.01% 701
2018
Q4 		$6.97M Sell
431,314
-134,360
-24% -$2.61M 0.01% 1160
2018
Q3 		$11.7M Buy
565,674
+15,850
+3% +$249K 0.01% 1020
2018
Q2 		$8.4M Buy
549,824
+102,385
+23% +$1.83M 0.01% 1264
2018
Q1 		$10.1M Sell
447,439
-161,061
-26% -$4.46M 0.01% 1113
2017
Q4 		$18.3M Sell
608,500
-204,800
-25% -$6.55M 0.01% 832
2017
Q3 		$30.6M Buy
813,300
+518,365
+176% +$16.9M 0.02% 593
2017
Q2 		$8.23M Sell
294,935
-11,694
-4% -$349K 0.01% 1258
2017
Q1 		$10.5M Buy
306,629
+12,096
+4% +$427K 0.01% 1095
2016
Q4 		$8.49M Sell
294,533
-2,526
-0.9% -$66.8K 0.01% 1230
2016
Q3 		$9.45M Sell
297,059
-86,381
-23% -$2.93M 0.01% 1158
2016
Q2 		$12.4M Buy
383,440
+19,138
+5% +$640K 0.01% 943
2016
Q1 		$10.2M Buy
364,302
+3,393
+0.9% +$74K 0.01% 1042
2015
Q4 		$12.9M Sell
360,909
-4,560
-1% -$161K 0.01% 932
2015
Q3 		$12.1M Buy
365,469
+2,768
+0.8% +$115K 0.01% 948
2015
Q2 		$15.2M Buy
362,701
+76,326
+27% +$2.95M 0.01% 908
2015
Q1 		$9.33M Buy
286,375
+4,749
+2% +$163K 0.01% 1192
2014
Q4 		$8.94M Sell
281,626
-33,244
-11% -$943K 0.01% 1194
2014
Q3 		$7.8M Sell
314,870
-83,853
-21% -$1.96M 0.01% 1274
2014
Q2 		$9.01M Buy
398,723
+3,398
+0.9% +$70.9K 0.01% 1241
2014
Q1 		$9.62M Buy
395,325
+15,837
+4% +$401K 0.01% 1165
2013
Q4 		$9.48M Sell
379,488
-6,756
-2% -$159K 0.01% 1187
2013
Q3 		$10.6M Buy
386,244
+14,181
+4% +$296K 0.01% 1055
2013
Q2 		$6.75M Buy
+372,063
New +$5.12M 0.01% 1295

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

TIAA CREF Investment Management's ACAD Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Acadia Pharmaceuticals (ACAD) stake by 77% in Q1 2019, buying an estimated $7.77M and bringing the position to 763,896 shares worth $20.5M. The position accounts for 0.01% of the portfolio, ranked #701.

TIAA CREF Investment Management first reported a position in ACAD in Q2 2013 and has held it in 24 quarters since. The position peaked at $30.6M in Q3 2017. 199 funds tracked by Wall St. Rank hold ACAD as of Q1 2019.

  • TIAA CREF Investment Management held 763,896 shares of Acadia Pharmaceuticals worth $20.5M as of Q1 2019.
  • TIAA CREF Investment Management bought 332,582 Acadia Pharmaceuticals shares in Q1 2019, an estimated $7.77M.
  • Acadia Pharmaceuticals made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #701 holding.
  • TIAA CREF Investment Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Acadia Pharmaceuticals position peaked at $30.6M in Q3 2017.
  • 199 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.